Global Argininemia Treatment Market
Global Argininemia Treatment Market

Argininemia Treatment Comprehensive Study by Type (Oral, Injection), End Users (Hospitals, Clinics, Therapeutic Centres), Category (Congenital and Genetic Diseases, Metabolic disorders, RDCRN), Treatment (Dietary Proteins, Nitrogen-Scavenging Medications, Intravenous (IV) Fluids, Amino Acids) Players and Region - Global Market Outlook to 2026

Argininemia Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Nov 2021 Edition 244 Pages 172 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Argininemia (ARG) is a disorder in which dangerous levels of arginine and ammonia accumulate in the body. It is classified as an amino acid disorder because persons with ARG are unable to break down arginine, an amino acid, a tiny molecule that builds up proteins. Treatment for arginine mix is nutritional, including protein restriction and amino acid supplementation. Individuals with arginine mix can typically live healthy lives if the illness is diagnosed early and effective therapy is undertaken.This growth is primarily driven by Increasing Incidents of Urea Cycle Disorders.

Globally, a noticeable market trend is evident The Emergence of Lipid Nanoparticle-Targeted mRNA Therapy. Major Players, such as BabyFirst (United States), Invitae (United States), TriHealth (United States), Aeglea Bio Therapeutics Inc (United States), Sigma-Aldrich (United States), R & D Systems (United States), ACROBiosystems (United States), Novus Biologicals (United States), VarSome (China) and Breda Genetics srl (Italy) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In May 2021 Aeglea BioTherapeutics released a statement announcing the commercial agreement with Immedica. The companies announced a licensing and supply agreement for pegzilarginase, a new recombinant human arginase 1 enzyme that has been found to reduce harmful levels of the amino acid arginine in patients with Arginase 1 Deficiency (ARG1-D) across Europe and the Middle East.

Market Drivers
  • Increasing Incidents of Urea Cycle Disorders

Market Trend
  • The Emergence of Lipid Nanoparticle-Targeted mRNA Therapy

Restraints
  • Argininemia Treatment May Cause Some Side Effects Such as Poor Growth and Stiff Muscles

Opportunities
Rise in Ammonia Deficiency in Babies
Challenges
Lack of Awareness Regarding Argininemia Treatment and Argininemia Treatment is Very Expensive

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Argininemia Treatment Study Sheds Light on
— The Argininemia Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Argininemia Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Argininemia Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Argininemia Treatment Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Argininemia Treatment Market?
Companies that are profiled in Global Argininemia Treatment Market are BabyFirst (United States), Invitae (United States), TriHealth (United States), Aeglea Bio Therapeutics Inc (United States), Sigma-Aldrich (United States), R & D Systems (United States), ACROBiosystems (United States), Novus Biologicals (United States), VarSome (China) and Breda Genetics srl (Italy) etc.

3. What is Argininemia Treatment Market?
Argininemia (ARG) is a disorder in which dangerous levels of arginine and ammonia accumulate in the body. It is classified as an amino acid disorder because persons with ARG are unable to break down arginine, an amino acid, a tiny molecule that builds up proteins. Treatment for arginine mix is nutritional, including protein restriction and amino acid supplementation. Individuals with arginine mix can typically live healthy lives if the illness is diagnosed early and effective therapy is undertaken.
Report Objectives / Segmentation Covered
By Type
  • Oral
  • Injection
By End Users
  • Hospitals
  • Clinics
  • Therapeutic Centres

By Category
  • Congenital and Genetic Diseases
  • Metabolic disorders
  • RDCRN

By Treatment
  • Dietary Proteins
  • Nitrogen-Scavenging Medications
  • Intravenous (IV) Fluids
  • Amino Acids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidents of Urea Cycle Disorders
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness Regarding Argininemia Treatment
      • 3.3.2. Argininemia Treatment is Very Expensive
    • 3.4. Market Trends
      • 3.4.1. The Emergence of Lipid Nanoparticle-Targeted mRNA Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Argininemia Treatment, by Type, End Users, Category, Treatment and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Argininemia Treatment (Value)
      • 5.2.1. Global Argininemia Treatment by: Type (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Injection
      • 5.2.2. Global Argininemia Treatment by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Therapeutic Centres
      • 5.2.3. Global Argininemia Treatment by: Category (Value)
        • 5.2.3.1. Congenital and Genetic Diseases
        • 5.2.3.2. Metabolic disorders
        • 5.2.3.3. RDCRN
      • 5.2.4. Global Argininemia Treatment by: Treatment (Value)
        • 5.2.4.1. Dietary Proteins
        • 5.2.4.2. Nitrogen-Scavenging Medications
        • 5.2.4.3. Intravenous (IV) Fluids
        • 5.2.4.4. Amino Acids
      • 5.2.5. Global Argininemia Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Argininemia Treatment (Price)
      • 5.3.1. Global Argininemia Treatment by: Type (Price)
  • 6. Argininemia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BabyFirst (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Invitae (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. TriHealth (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aeglea Bio Therapeutics Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sigma-Aldrich (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. R & D Systems (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ACROBiosystems (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novus Biologicals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. VarSome (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Breda Genetics srl (Italy)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Argininemia Treatment Sale, by Type, End Users, Category, Treatment and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Argininemia Treatment (Value)
      • 7.2.1. Global Argininemia Treatment by: Type (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Injection
      • 7.2.2. Global Argininemia Treatment by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Therapeutic Centres
      • 7.2.3. Global Argininemia Treatment by: Category (Value)
        • 7.2.3.1. Congenital and Genetic Diseases
        • 7.2.3.2. Metabolic disorders
        • 7.2.3.3. RDCRN
      • 7.2.4. Global Argininemia Treatment by: Treatment (Value)
        • 7.2.4.1. Dietary Proteins
        • 7.2.4.2. Nitrogen-Scavenging Medications
        • 7.2.4.3. Intravenous (IV) Fluids
        • 7.2.4.4. Amino Acids
      • 7.2.5. Global Argininemia Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Argininemia Treatment (Price)
      • 7.3.1. Global Argininemia Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Argininemia Treatment: by Type(USD Million)
  • Table 2. Argininemia Treatment Oral , by Region USD Million (2015-2020)
  • Table 3. Argininemia Treatment Injection , by Region USD Million (2015-2020)
  • Table 4. Argininemia Treatment: by End Users(USD Million)
  • Table 5. Argininemia Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 6. Argininemia Treatment Clinics , by Region USD Million (2015-2020)
  • Table 7. Argininemia Treatment Therapeutic Centres , by Region USD Million (2015-2020)
  • Table 8. Argininemia Treatment: by Category(USD Million)
  • Table 9. Argininemia Treatment Congenital and Genetic Diseases , by Region USD Million (2015-2020)
  • Table 10. Argininemia Treatment Metabolic disorders , by Region USD Million (2015-2020)
  • Table 11. Argininemia Treatment RDCRN , by Region USD Million (2015-2020)
  • Table 12. Argininemia Treatment: by Treatment(USD Million)
  • Table 13. Argininemia Treatment Dietary Proteins , by Region USD Million (2015-2020)
  • Table 14. Argininemia Treatment Nitrogen-Scavenging Medications , by Region USD Million (2015-2020)
  • Table 15. Argininemia Treatment Intravenous (IV) Fluids , by Region USD Million (2015-2020)
  • Table 16. Argininemia Treatment Amino Acids , by Region USD Million (2015-2020)
  • Table 17. South America Argininemia Treatment, by Country USD Million (2015-2020)
  • Table 18. South America Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 19. South America Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 20. South America Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 21. South America Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 22. Brazil Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 23. Brazil Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 24. Brazil Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 25. Brazil Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 26. Argentina Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 27. Argentina Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 28. Argentina Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 29. Argentina Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 30. Rest of South America Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 32. Rest of South America Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 33. Rest of South America Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 34. Asia Pacific Argininemia Treatment, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 37. Asia Pacific Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 38. Asia Pacific Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 39. China Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 40. China Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 41. China Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 42. China Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 43. Japan Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 44. Japan Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 45. Japan Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 46. Japan Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 47. India Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 48. India Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 49. India Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 50. India Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 51. South Korea Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 52. South Korea Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 53. South Korea Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 54. South Korea Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 55. Australia Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 56. Australia Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 57. Australia Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 58. Australia Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 63. Europe Argininemia Treatment, by Country USD Million (2015-2020)
  • Table 64. Europe Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 65. Europe Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 66. Europe Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 67. Europe Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 68. Germany Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 69. Germany Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 70. Germany Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 71. Germany Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 72. France Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 73. France Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 74. France Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 75. France Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 76. Italy Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 77. Italy Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 78. Italy Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 79. Italy Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 80. United Kingdom Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 81. United Kingdom Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 82. United Kingdom Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 83. United Kingdom Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 84. Netherlands Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 85. Netherlands Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 86. Netherlands Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 87. Netherlands Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 88. Rest of Europe Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 89. Rest of Europe Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 90. Rest of Europe Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 91. Rest of Europe Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 92. MEA Argininemia Treatment, by Country USD Million (2015-2020)
  • Table 93. MEA Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 94. MEA Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 95. MEA Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 96. MEA Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 97. Middle East Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 98. Middle East Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 99. Middle East Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 100. Middle East Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 101. Africa Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 102. Africa Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 103. Africa Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 104. Africa Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 105. North America Argininemia Treatment, by Country USD Million (2015-2020)
  • Table 106. North America Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 107. North America Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 108. North America Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 109. North America Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 110. United States Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 111. United States Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 112. United States Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 113. United States Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 114. Canada Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 115. Canada Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 116. Canada Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 117. Canada Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 118. Mexico Argininemia Treatment, by Type USD Million (2015-2020)
  • Table 119. Mexico Argininemia Treatment, by End Users USD Million (2015-2020)
  • Table 120. Mexico Argininemia Treatment, by Category USD Million (2015-2020)
  • Table 121. Mexico Argininemia Treatment, by Treatment USD Million (2015-2020)
  • Table 122. Argininemia Treatment: by Type(USD/Units)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Argininemia Treatment: by Type(USD Million)
  • Table 134. Argininemia Treatment Oral , by Region USD Million (2021-2026)
  • Table 135. Argininemia Treatment Injection , by Region USD Million (2021-2026)
  • Table 136. Argininemia Treatment: by End Users(USD Million)
  • Table 137. Argininemia Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 138. Argininemia Treatment Clinics , by Region USD Million (2021-2026)
  • Table 139. Argininemia Treatment Therapeutic Centres , by Region USD Million (2021-2026)
  • Table 140. Argininemia Treatment: by Category(USD Million)
  • Table 141. Argininemia Treatment Congenital and Genetic Diseases , by Region USD Million (2021-2026)
  • Table 142. Argininemia Treatment Metabolic disorders , by Region USD Million (2021-2026)
  • Table 143. Argininemia Treatment RDCRN , by Region USD Million (2021-2026)
  • Table 144. Argininemia Treatment: by Treatment(USD Million)
  • Table 145. Argininemia Treatment Dietary Proteins , by Region USD Million (2021-2026)
  • Table 146. Argininemia Treatment Nitrogen-Scavenging Medications , by Region USD Million (2021-2026)
  • Table 147. Argininemia Treatment Intravenous (IV) Fluids , by Region USD Million (2021-2026)
  • Table 148. Argininemia Treatment Amino Acids , by Region USD Million (2021-2026)
  • Table 149. South America Argininemia Treatment, by Country USD Million (2021-2026)
  • Table 150. South America Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 151. South America Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 152. South America Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 153. South America Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 154. Brazil Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 155. Brazil Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 156. Brazil Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 157. Brazil Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 158. Argentina Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 159. Argentina Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 160. Argentina Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 161. Argentina Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 162. Rest of South America Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 163. Rest of South America Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 164. Rest of South America Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 165. Rest of South America Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 166. Asia Pacific Argininemia Treatment, by Country USD Million (2021-2026)
  • Table 167. Asia Pacific Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 168. Asia Pacific Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 169. Asia Pacific Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 170. Asia Pacific Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 171. China Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 172. China Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 173. China Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 174. China Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 175. Japan Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 176. Japan Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 177. Japan Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 178. Japan Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 179. India Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 180. India Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 181. India Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 182. India Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 183. South Korea Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 184. South Korea Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 185. South Korea Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 186. South Korea Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 187. Australia Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 188. Australia Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 189. Australia Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 190. Australia Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 191. Rest of Asia-Pacific Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 192. Rest of Asia-Pacific Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 194. Rest of Asia-Pacific Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 195. Europe Argininemia Treatment, by Country USD Million (2021-2026)
  • Table 196. Europe Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 197. Europe Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 198. Europe Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 199. Europe Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 200. Germany Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 201. Germany Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 202. Germany Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 203. Germany Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 204. France Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 205. France Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 206. France Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 207. France Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 208. Italy Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 209. Italy Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 210. Italy Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 211. Italy Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 212. United Kingdom Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 213. United Kingdom Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 214. United Kingdom Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 215. United Kingdom Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 216. Netherlands Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 217. Netherlands Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 218. Netherlands Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 219. Netherlands Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 220. Rest of Europe Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 221. Rest of Europe Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 222. Rest of Europe Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 223. Rest of Europe Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 224. MEA Argininemia Treatment, by Country USD Million (2021-2026)
  • Table 225. MEA Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 226. MEA Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 227. MEA Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 228. MEA Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 229. Middle East Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 230. Middle East Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 231. Middle East Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 232. Middle East Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 233. Africa Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 234. Africa Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 235. Africa Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 236. Africa Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 237. North America Argininemia Treatment, by Country USD Million (2021-2026)
  • Table 238. North America Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 239. North America Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 240. North America Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 241. North America Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 242. United States Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 243. United States Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 244. United States Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 245. United States Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 246. Canada Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 247. Canada Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 248. Canada Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 249. Canada Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 250. Mexico Argininemia Treatment, by Type USD Million (2021-2026)
  • Table 251. Mexico Argininemia Treatment, by End Users USD Million (2021-2026)
  • Table 252. Mexico Argininemia Treatment, by Category USD Million (2021-2026)
  • Table 253. Mexico Argininemia Treatment, by Treatment USD Million (2021-2026)
  • Table 254. Argininemia Treatment: by Type(USD/Units)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Argininemia Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Argininemia Treatment: by End Users USD Million (2015-2020)
  • Figure 6. Global Argininemia Treatment: by Category USD Million (2015-2020)
  • Figure 7. Global Argininemia Treatment: by Treatment USD Million (2015-2020)
  • Figure 8. South America Argininemia Treatment Share (%), by Country
  • Figure 9. Asia Pacific Argininemia Treatment Share (%), by Country
  • Figure 10. Europe Argininemia Treatment Share (%), by Country
  • Figure 11. MEA Argininemia Treatment Share (%), by Country
  • Figure 12. North America Argininemia Treatment Share (%), by Country
  • Figure 13. Global Argininemia Treatment: by Type USD/Units (2015-2020)
  • Figure 14. Global Argininemia Treatment share by Players 2020 (%)
  • Figure 15. Global Argininemia Treatment share by Players (Top 3) 2020(%)
  • Figure 16. Global Argininemia Treatment share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. BabyFirst (United States) Revenue, Net Income and Gross profit
  • Figure 19. BabyFirst (United States) Revenue: by Geography 2020
  • Figure 20. Invitae (United States) Revenue, Net Income and Gross profit
  • Figure 21. Invitae (United States) Revenue: by Geography 2020
  • Figure 22. TriHealth (United States) Revenue, Net Income and Gross profit
  • Figure 23. TriHealth (United States) Revenue: by Geography 2020
  • Figure 24. Aeglea Bio Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. Aeglea Bio Therapeutics Inc (United States) Revenue: by Geography 2020
  • Figure 26. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 27. Sigma-Aldrich (United States) Revenue: by Geography 2020
  • Figure 28. R & D Systems (United States) Revenue, Net Income and Gross profit
  • Figure 29. R & D Systems (United States) Revenue: by Geography 2020
  • Figure 30. ACROBiosystems (United States) Revenue, Net Income and Gross profit
  • Figure 31. ACROBiosystems (United States) Revenue: by Geography 2020
  • Figure 32. Novus Biologicals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Novus Biologicals (United States) Revenue: by Geography 2020
  • Figure 34. VarSome (China) Revenue, Net Income and Gross profit
  • Figure 35. VarSome (China) Revenue: by Geography 2020
  • Figure 36. Breda Genetics srl (Italy) Revenue, Net Income and Gross profit
  • Figure 37. Breda Genetics srl (Italy) Revenue: by Geography 2020
  • Figure 38. Global Argininemia Treatment: by Type USD Million (2021-2026)
  • Figure 39. Global Argininemia Treatment: by End Users USD Million (2021-2026)
  • Figure 40. Global Argininemia Treatment: by Category USD Million (2021-2026)
  • Figure 41. Global Argininemia Treatment: by Treatment USD Million (2021-2026)
  • Figure 42. South America Argininemia Treatment Share (%), by Country
  • Figure 43. Asia Pacific Argininemia Treatment Share (%), by Country
  • Figure 44. Europe Argininemia Treatment Share (%), by Country
  • Figure 45. MEA Argininemia Treatment Share (%), by Country
  • Figure 46. North America Argininemia Treatment Share (%), by Country
  • Figure 47. Global Argininemia Treatment: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • BabyFirst (United States)
  • Invitae (United States)
  • TriHealth (United States)
  • Aeglea Bio Therapeutics Inc (United States)
  • Sigma-Aldrich (United States)
  • R & D Systems (United States)
  • ACROBiosystems (United States)
  • Novus Biologicals (United States)
  • VarSome (China)
  • Breda Genetics srl (Italy)
Additional players considered in the study are as follows:
Orphanet (France) , Mendelian Health (United Kingdom) , Asbbs (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation